Incyte Corporation (INCY) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Wait for pullback to $88.59. BUY gates pass at $98.56, but concentration risk — Product: JAKAFI and concentration risk — Customer: specialty pharmacies and wholesalers argue for a more patient entry. Engine's entry $88.59 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum.
Incyte is a global biopharma with commercial products in Hematology (JAKAFI, ICLUSIG, MONJUVI/MINJUVI, NIKTIMVO), Oncology (PEMAZYRE, ZYNYZ), and Inflammation/Autoimmunity (OPZELURA). JAKAFI (ruxolitinib) is the flagship revenue driver; ex-U.S. rights licensed to Novartis.
Wait for pullback to $88.59. BUY gates pass at $98.56, but concentration risk — Product: JAKAFI and concentration risk — Customer: specialty pharmacies and wholesalers argue for a more patient entry. Engine's entry $88.59 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Golden cross, above all MAs, RSI 54, MACD bullish. Fundamentals strong but target reached (-0.9% upside). Wait for pullback. Score 7.1/10, moderate confidence.
Passes 5/6 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 78d clear, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductJAKAFI10-K Item 1A: 'We depend heavily on JAKAFI/JAKAVI (ruxolitinib), and if we are not able to maintain revenues from JAKAFI/JAKAVI or those revenues decrease, our business may be materially harmed.'
- HIGHCustomerspecialty pharmacies and wholesalers10-K Item 1A: 'A limited number of specialty pharmacies and wholesalers represent a significant portion of revenues from JAKAFI and most of our other products'
Material Events(8-K, last 90d)
- 2026-03-30Item 5.02LOWDirector Susanne Schaffert resigned from Board effective April 15, 2026; Board member since 2022. No disagreement with Company operations cited.SEC filing →
- 2026-03-26Item 5.02LOWExecutive title changes effective March 25, 2026: Cagnoni becomes President Incyte; Stein becomes EVP CMO Head of Late-stage Development; Issa becomes EVP Head of U.S. Commercial. Meury remains CEO.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $88.59. BUY gates pass at $98.56, but concentration risk — Product: JAKAFI and concentration risk — Customer: specialty pharmacies and wholesalers argue for a more patient entry. Engine's entry $88.59 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Golden cross, above all MAs, RSI 54, MACD bullish. Fundamentals strong but target reached (-0.9% upside). Wait for pullback. Target $100.80 (+2.3%), stop $82.42 (−19.6%), Setup A.R:R 1.6:1. Score 7.1/10, moderate confidence.
Take-profit target: $100.80 (+7.0% upside). Target $100.80 (+2.3%), stop $82.42 (−19.6%), Setup A.R:R 1.6:1. Stop-loss: $82.42.
Concentration risk — Product: JAKAFI; Concentration risk — Customer: specialty pharmacies and wholesalers; Analyst target reached - limited upside remaining.
Incyte Corporation trades at a P/E of 13.9 (forward 10.9). TrendMatrix value score: 7.5/10. Verdict: Buy (Wait for Entry).
33 analysts cover INCY with a consensus score of 3.7/5. Average price target: $109.
What does Incyte Corporation do?Incyte is a global biopharma with commercial products in Hematology (JAKAFI, ICLUSIG, MONJUVI/MINJUVI, NIKTIMVO),...
Incyte is a global biopharma with commercial products in Hematology (JAKAFI, ICLUSIG, MONJUVI/MINJUVI, NIKTIMVO), Oncology (PEMAZYRE, ZYNYZ), and Inflammation/Autoimmunity (OPZELURA). JAKAFI (ruxolitinib) is the flagship revenue driver; ex-U.S. rights licensed to Novartis.